These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26759348)

  • 1. Nivolumab-induced organizing pneumonia in a melanoma patient.
    Sano T; Uhara H; Mikoshiba Y; Kobayashi A; Uchiyama R; Tateishi K; Yamamoto H; Okuyama R
    Jpn J Clin Oncol; 2016 Mar; 46(3):270-2. PubMed ID: 26759348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
    Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
    Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).
    Ishiwata T; Ebata T; Iwasawa S; Matsushima J; Ota S; Nakatani Y; Tsushima K; Tada Y; Tatsumi K; Takiguchi Y
    Intern Med; 2017 Sep; 56(17):2311-2315. PubMed ID: 28794361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
    Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
    Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
    Mahjoubi L; Gazzah A; Marabelle A; Le Roy Ladurie F; Lambotte O; Caramella C; Adam J; Besse B; Soria JC
    Eur J Cancer; 2017 Nov; 85():155-157. PubMed ID: 28917814
    [No Abstract]   [Full Text] [Related]  

  • 6. Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
    Miyazawa H; Yanagi T; Yamaguchi Y; Imafuku K; Kitamura S; Hata H; Uehara J; Ichikawa N; Ohno Y; Yoshida T; Homma S; Kawamura H; Taketomi A; Shimizu H
    J Dermatol; 2017 Aug; 44(8):959-962. PubMed ID: 28295515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma.
    El Ati Z; Lamia R; Cherif J; Jbali H; Fatma LB; Mami I; Khedher R; Smaoui W; Krid M; Hamida FB; Beji S; Zouaghi MK
    Saudi J Kidney Dis Transpl; 2019; 30(4):974-977. PubMed ID: 31464258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
    Inoue K; Tsubamoto H; Isono-Nakata R; Sakata K; Nakagomi N
    BMC Cancer; 2018 Jun; 18(1):630. PubMed ID: 29866134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
    Diamantopoulos PT; Gaggadi M; Kassi E; Benopoulou O; Anastasopoulou A; Gogas H
    Melanoma Res; 2017 Aug; 27(4):391-395. PubMed ID: 28419059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    Ozaki Y; Shindoh J; Miura Y; Nakajima H; Oki R; Uchiyama M; Masuda J; Kinowaki K; Kondoh C; Tanabe Y; Tanaka T; Haruta S; Ueno M; Kitano S; Fujii T; Udagawa H; Takano T
    BMC Cancer; 2017 Nov; 17(1):778. PubMed ID: 29162045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
    Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
    Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
    J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
    Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
    Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?
    Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390
    [No Abstract]   [Full Text] [Related]  

  • 20. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
    Maur M; Tomasello C; Frassoldati A; Dieci MV; Barbieri E; Conte P
    J Clin Oncol; 2012 Feb; 30(6):e76-8. PubMed ID: 22203769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.